e-Stella innovation: precision, efficiency, reliability
E-Stella is a scoring tool to help decision making during a liver harvesting. With the support of Artificial Intelligence (AI), our technology allows to classify and measure with precision the steatosis rate of a liver, which is essential during a liver transplantation.
Click here for more details about the impact of steatosis rate on transplantation.
To date, E-Stella is available to provide a trust index to surgeons in order to facilitate decision making during liver transplantation*.
A future version is currently at the clinical evaluation phase, in cooperation with 3 AP-HP institutes: Pitié-Salpêtrière Hospital, Paul-Brousse Hospital and Beaujon Hospital.
Because the safety and performance of our technologies are at the heart of our concerns, a pilot study is driven by five surgeons: Prof. Olivier Scatton, Dr. Claire Goumard, Prof. Eric Vibert, Dr. Nicolas Golse, and Prof. Olivier Soubrane.
E-Stella is also undergoing certification for CE and FDA marking as a Class IIa medical device under the new Regulation (EU) 2017/745 on medical devices.
Why choose e-Stella ?
For surgical teams
Provides a trust index on the reliability of the liver graft in real time.
Save time and efficiency by optimizing the work of the transplant teams.
Detects “marginal” transplantable livers, thus reducing the number of undiagnosed viable grafts.
For the health care facilities
Avoids expensive and risky travels for surgical teams and organ transporters. They will no longer have to travel without knowing the viability of the liver graft.
First scoring technology to support surgeons’ decision-making.
Avoids expensive and invasive procedures.
For the patients
Each patient waiting for a liver transplant can ask his or her surgeon to perform an evaluation of his or her future graft with E-Stella, in order to secure and maximize his or her post-operative recover.
Increases the number of transplants and grafts available.
To ensure transparent and ethical business conduct, Stella Surgical has collaborated with public research teams and world-renowned hospitals to provide conclusive scientific publications.
USE OF ARTIFICIAL INTELLIGENCE AS AN INNOVATIVE METHOD FOR LIVER GRAFT MACROSTEATOSIS ASSESSMENT
AASLD – Volume 26, Issue 10, October 2020 – p. 1224-1232
Authors: Manuela Cesaretti,Raffaele Brustia,Claire Goumard,François Cauchy,Nicolas Poté,Federica Dondero,Catherine Paugam-Burtz,François Durand,Valerie Paradis,Alberto Diaspro,Leonardo Mattos,Olivier Scatton,Olivier Soubrane,Sara Moccia
ASSESSMENT OF LIVER GRAFT STEATOSIS: WHERE DO WE STAND?
AASLD – Volume 25, Issue 3, March 2019 – p. 500-509
Authors: Manuela Cesaretti,Pietro Addeo,Luigi Schiavo,Rodolphe Anty,Antonio Iannelli.
NONINVASIVE ASSESSEMENT OF LIVER STEATOSIS IN DECEASED DONORS: A PILOT STUDY
AASLD – Volume 24, Issue 4, April 2018 – p. 551-556
Authors: Manuela Cesaretti M.D.,Nicolas Poté M.D.,Francois Cauchy M.D.,Federica Dondero M.D.,Safi Dokmak M.D.,Ailton Sepulveda M.D.,Anne Sophie Schneck M.D.,Claire Francoz M.D., Ph.D.,Francois Durand M.D., Ph.D.,Valerie Paradis M.D., Ph.D.,Olivier Soubrane M.D., Ph.D.
COMPUTER-ASSISTED LIVER GRAFT STEATOSIS ASSESSMENT VIA LEARNING-BASED TEXTURE ANALYSIS
IJCARS – Volume 13, Issue 9, September 2018 – p. 1357-1367
Authors: Sara Moccia, Leonardo S. Mattos, Ilaria Patrini, Michela Ruperti, Nicolas Poté, Federica Dondero, François Cauchy, Ailton Sepulveda, Olivier Soubrane, Elena De Momi, Alberto Diaspro & Manuela Cesaretti.